- Home
- SITC vs PROK Comparison
SITC vs PROK Comparison
Compare SITC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | PROK |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 417.1M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | SITC | PROK |
|---|---|---|
| Price | $7.30 | $2.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $12.63 | $6.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 78.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $139,962,000.00 | $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.76 | $0.46 |
| 52 Week High | $15.93 | $7.13 |
Technical Indicators
Market Signals| Indicator | SITC | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 44.95 |
| Support Level | $7.17 | $2.04 |
| Resistance Level | $7.41 | $2.25 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 73.29 | 45.90 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.